On Nov 10, 2018 Tracon Pharmaceuticals Inc (NASDAQ:TCON) Sellers Strengthened Their Shorts By 11.92%

TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Corporate Logo

Tracon Pharmaceuticals Inc (NASDAQ:TCON) had an increase of its short interest by 11.92%. In November was announced TCON’s total 205,700 short interest by FINRA. That’s 11.92% up from 183,800 shares. 2 days will cost TCON with 119,900 average volume to recover its previous position. Tracon Pharmaceuticals Inc float short is 1.42%.

Ticker’s shares touched $1.43 during the last trading session after 4.67% change.TRACON Pharmaceuticals, Inc. is downtrending after having declined 34.33% since November 10, 2017. TCON has 107,287 volume or 8.53% up from normal. TCON underperformed by 49.95% the S&P500.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases.The firm is valued at $42.67 million. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD.Currently it has negative earnings. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

For more TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news announced briefly go to: Seekingalpha.com, Nasdaq.com, Benzinga.com, Uk.Finance.Yahoo.com or Benzinga.com. The titles are as follows: “TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q3 2018 Results – Earnings Call Transcript” announced on November 08, 2018, “TRACON to Report Third Quarter 2018 Company Highlights and Financial Results on November 7, 2018” on October 31, 2018, “The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie” with a publish date: November 07, 2018, “Shareholders Should Check The Ownership Structure Of TRACON Pharmaceuticals Inc (NASDAQ:TCON)” and the last “The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs” with publication date: November 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.